Xie Xuping, Zou Jing, Fontes-Garfias Camila R, Xia Hongjie, Swanson Kena A, Cutler Mark, Cooper David, Menachery Vineet D, Weaver Scott, Dormitzer Philip R, Shi Pei-Yong
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, U.S.A.
Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.
bioRxiv. 2021 Jan 7:2021.01.07.425740. doi: 10.1101/2021.01.07.425740.
Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.
在英国和南非出现的快速传播的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体都有刺突蛋白N501Y替代，这尤其令人担忧，因为它位于病毒进入细胞的受体结合位点，并且增加了与受体（血管紧张素转换酶2）的结合。我们构建了同基因的N501和Y501 SARS-CoV-2。在先前一项基于信使核糖核酸的2019冠状病毒病（COVID-19）疫苗BNT162b2试验中的20名参与者的血清对N501和Y501病毒具有同等的中和效价。
